Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이창범 | - |
dc.date.accessioned | 2017-03-22T05:47:51Z | - |
dc.date.available | 2017-03-22T05:47:51Z | - |
dc.date.issued | 2015-07 | - |
dc.identifier.citation | Endocrinology and Metabolism, v. 30, NO 3, Page. 272-279 | en_US |
dc.identifier.issn | 2093-596X | - |
dc.identifier.issn | 2093-5978 | - |
dc.identifier.uri | https://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2015.30.3.272 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/26255 | - |
dc.description.abstract | Background The present study evaluated the efficacy of a combination of ibandronate and cholecalciferol on the restoration of the levels of 25-hydroxyvitamin D (25[OH]D) and various bone markers in postmenopausal women with osteoporosis. Methods This was a randomized, double-blind, active-controlled, prospective 16-week clinical trial conducted in 20 different hospitals. A total of 201 postmenopausal women with osteoporosis were assigned randomly to one of two groups: the IBN group, which received a once-monthly pill containing 150 mg ibandronate (n=99), or the IBN+ group, which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol (n=102). Serum levels of 25(OH)D, parathyroid hormone (PTH), and various bone markers were assessed at baseline and at the end of a 16-week treatment period. Results After 16 weeks of treatment, the mean serum levels of 25(OH)D significantly increased from 21.0 to 25.3 ng/mL in the IBN+ group but significantly decreased from 20.6 to 17.4 ng/mL in the IBN group. Additionally, both groups exhibited significant increases in mean serum levels of PTH but significant decreases in serum levels of bone-specific alkaline phosphatase and C-telopeptide of type 1 collagen (CTX) at 16 weeks; no significant differences were observed between the groups. However, in subjects with a vitamin D deficiency, IBN+ treatment resulted in a significant decrease in serum CTX levels compared with IBN treatment. Conclusion The present findings demonstrate that a once-monthly pill containing ibandronate and cholecalciferol may be useful for the amelioration of vitamin D deficiency in patients with postmenopausal osteoporosis. Moreover, this treatment combination effectively decreased serum levels of resorption markers, especially in subjects with a vitamin D deficiency, over the 16-week treatment period. | en_US |
dc.description.sponsorship | This study was supported by Dreampharma Corp., of Seoul, Korea. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Korean Endocrine Society | en_US |
dc.subject | Ibandronate | en_US |
dc.subject | Cholecalciferol | en_US |
dc.subject | 25-hydroxyvitamin D | en_US |
dc.subject | Bone markers | en_US |
dc.title | Efficacy of a once-monthly pill containing ibandronate and cholecalciferol on the levels of 25-hydroxyvitamin D and bone markers in postmenopausal women with osteoporosis | en_US |
dc.type | Article | en_US |
dc.relation.no | 3 | - |
dc.relation.volume | 30 | - |
dc.identifier.doi | 10.3803/EnM.2015.30.3.272 | - |
dc.relation.page | 272-279 | - |
dc.relation.journal | Endocrinology and Metabolism Clinics of North America | - |
dc.contributor.googleauthor | Cho, In-Jin | - |
dc.contributor.googleauthor | Chung, Ho-Yeon | - |
dc.contributor.googleauthor | Kim, Sung-Woon | - |
dc.contributor.googleauthor | Lee, Jae-Won | - |
dc.contributor.googleauthor | Lee, Tae-Won | - |
dc.contributor.googleauthor | Kim, Hye-Soon | - |
dc.contributor.googleauthor | Kim, Sin-Gon | - |
dc.contributor.googleauthor | Choi, Han Seok | - |
dc.contributor.googleauthor | Choi, Sung-Hee | - |
dc.contributor.googleauthor | Lee, Chang Beom | - |
dc.relation.code | 2015023273 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | lekang | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.